These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26496242)

  • 1. Evaluation of Improved Glycogen Synthase Kinase-3α Inhibitors in Models of Acute Myeloid Leukemia.
    Neumann T; Benajiba L; Göring S; Stegmaier K; Schmidt B
    J Med Chem; 2015 Nov; 58(22):8907-19. PubMed ID: 26496242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.
    Lo Monte F; Kramer T; Gu J; Anumala UR; Marinelli L; La Pietra V; Novellino E; Franco B; Demedts D; Van Leuven F; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
    J Med Chem; 2012 May; 55(9):4407-24. PubMed ID: 22533818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
    Wang Y; Dou X; Jiang L; Jin H; Zhang L; Zhang L; Liu Z
    Eur J Med Chem; 2019 Jun; 171():221-234. PubMed ID: 30925338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based optimization of oxadiazole-based GSK-3 inhibitors.
    Lo Monte F; Kramer T; Gu J; Brodrecht M; Pilakowski J; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
    Eur J Med Chem; 2013 Mar; 61():26-40. PubMed ID: 22749643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycogen synthase kinase--3β inhibitors suppress leukemia cell growth.
    Song EY; Palladinetti P; Klamer G; Ko KH; Lindeman R; O'Brien TA; Dolnikov A
    Exp Hematol; 2010 Oct; 38(10):908-921.e1. PubMed ID: 20540984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological inhibitors of glycogen synthase kinase 3.
    Meijer L; Flajolet M; Greengard P
    Trends Pharmacol Sci; 2004 Sep; 25(9):471-80. PubMed ID: 15559249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.
    Banerji V; Frumm SM; Ross KN; Li LS; Schinzel AC; Hahn CK; Kakoza RM; Chow KT; Ross L; Alexe G; Tolliday N; Inguilizian H; Galinsky I; Stone RM; DeAngelo DJ; Roti G; Aster JC; Hahn WC; Kung AL; Stegmaier K
    J Clin Invest; 2012 Mar; 122(3):935-47. PubMed ID: 22326953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.
    Wagner FF; Benajiba L; Campbell AJ; Weïwer M; Sacher JR; Gale JP; Ross L; Puissant A; Alexe G; Conway A; Back M; Pikman Y; Galinsky I; DeAngelo DJ; Stone RM; Kaya T; Shi X; Robers MB; Machleidt T; Wilkinson J; Hermine O; Kung A; Stein AJ; Lakshminarasimhan D; Hemann MT; Scolnick E; Zhang YL; Pan JQ; Stegmaier K; Holson EB
    Sci Transl Med; 2018 Mar; 10(431):. PubMed ID: 29515000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GSK3 Deficiencies in Hematopoietic Stem Cells Initiate Pre-neoplastic State that Is Predictive of Clinical Outcomes of Human Acute Leukemia.
    Guezguez B; Almakadi M; Benoit YD; Shapovalova Z; Rahmig S; Fiebig-Comyn A; Casado FL; Tanasijevic B; Bresolin S; Masetti R; Doble BW; Bhatia M
    Cancer Cell; 2016 Jan; 29(1):61-74. PubMed ID: 26766591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer.
    Darrington RS; Campa VM; Walker MM; Bengoa-Vergniory N; Gorrono-Etxebarria I; Uysal-Onganer P; Kawano Y; Waxman J; Kypta RM
    Int J Cancer; 2012 Sep; 131(6):E872-83. PubMed ID: 22539113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of glycogen synthase kinase 3beta during heart failure is protective.
    Hirotani S; Zhai P; Tomita H; Galeotti J; Marquez JP; Gao S; Hong C; Yatani A; Avila J; Sadoshima J
    Circ Res; 2007 Nov; 101(11):1164-74. PubMed ID: 17901358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fine-Tuning of the RIG-I-Like Receptor/Interferon Regulatory Factor 3-Dependent Antiviral Innate Immune Response by the Glycogen Synthase Kinase 3/β-Catenin Pathway.
    Khan KA; Dô F; Marineau A; Doyon P; Clément JF; Woodgett JR; Doble BW; Servant MJ
    Mol Cell Biol; 2015 Sep; 35(17):3029-43. PubMed ID: 26100021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Wnt pool of glycogen synthase kinase 3beta is critical for trophic-deprivation-induced neuronal death.
    Hongisto V; Vainio JC; Thompson R; Courtney MJ; Coffey ET
    Mol Cell Biol; 2008 Mar; 28(5):1515-27. PubMed ID: 18195042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-3 beta (GSK-3 beta) inhibitors.
    Shen L; Prouty C; Conway BR; Westover L; Xu JZ; Look RA; Chen X; Beavers MP; Roberts J; Murray WV; Demarest KT; Kuo GH
    Bioorg Med Chem; 2004 Mar; 12(5):1239-55. PubMed ID: 14980636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and regulation of glycogen synthase kinase 3 in human neutrophils.
    Giambelluca MS; Cloutier N; Rollet-Labelle E; Boilard E; Pouliot M
    Int J Biochem Cell Biol; 2013 Nov; 45(11):2660-5. PubMed ID: 24035907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo.
    Kulkarni NH; Onyia JE; Zeng Q; Tian X; Liu M; Halladay DL; Frolik CA; Engler T; Wei T; Kriauciunas A; Martin TJ; Sato M; Bryant HU; Ma YL
    J Bone Miner Res; 2006 Jun; 21(6):910-20. PubMed ID: 16753022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organometallic compounds with biological activity: a very selective and highly potent cellular inhibitor for glycogen synthase kinase 3.
    Atilla-Gokcumen GE; Williams DS; Bregman H; Pagano N; Meggers E
    Chembiochem; 2006 Sep; 7(9):1443-50. PubMed ID: 16858717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxazolo[5,4-f]quinoxaline-type selective inhibitors of glycogen synthase kinase-3α (GSK-3α): Development and impact on temozolomide treatment of glioblastoma cells.
    Hasyeoui M; Lassagne F; Erb W; Nael M; Elokely KM; Chaikuad A; Knapp S; Jorda A; Vallés SL; Quissac E; Verreault M; Robert T; Bach S; Samarat A; Mongin F
    Bioorg Chem; 2023 May; 134():106456. PubMed ID: 36913879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and evaluation of 3-aryl-4-pyrrolyl-maleimides as glycogen synthase kinase-3β inhibitors.
    Ye Q; Li M; Zhou YB; Cao JY; Xu L; Li YJ; Han L; Gao JR; Hu YZ; Li J
    Arch Pharm (Weinheim); 2013 May; 346(5):349-58. PubMed ID: 23585245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.
    Kuo GH; Prouty C; DeAngelis A; Shen L; O'Neill DJ; Shah C; Connolly PJ; Murray WV; Conway BR; Cheung P; Westover L; Xu JZ; Look RA; Demarest KT; Emanuel S; Middleton SA; Jolliffe L; Beavers MP; Chen X
    J Med Chem; 2003 Sep; 46(19):4021-31. PubMed ID: 12954055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.